Bausch Health (BHC) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on May 19, 2026, to elect ten directors, approve executive compensation, and appoint PwC as auditor until 2027.

• Shareholders of record as of March 20, 2026, are entitled to vote; proxy materials are available online and by mail.

• The Board unanimously recommends voting FOR all proposals, including director nominees, executive compensation, and auditor appointment.

• Forward-looking statements are included, subject to risks detailed in the company’s filings.

Voting matters and shareholder proposals

• Proposals include electing ten directors, an advisory vote on executive compensation, and appointing PwC as auditor.

• Shareholders may submit proposals and director nominations for the 2027 meeting by specified deadlines.

• The Board is not aware of any other matters to be brought before the meeting.

Board of directors and corporate governance

• Nine of ten director nominees are independent; the Board is led by a non-executive Chairperson.

• Recent board refreshment added expertise in pharmaceuticals and governance; average director tenure is 5.6 years.

• Board committees include Audit and Risk, Talent and Compensation, Nominating and Corporate Governance, and Science and Technology.

• Directors are subject to share ownership guidelines and annual self-assessments.

• The Board meets at least four times per year, with high attendance and regular executive sessions of independent directors.